Status of DNDi clinical trials during the COVID-19 pandemic
While exploring how DNDi can lend support, capacity, assets, and expertise in support of the COVID-19 response in resource-constrained settings, our top priority is to ensure the health, safety, and well-being of the people currently enrolled in our clinical trials, and of our staff and partners. Many of the people participating in clinical studies have serious illnesses, some life-threatening, for which they are receiving treatment. DNDi has a duty of care to continue their treatment during this time while ensuring their safety, maintaining compliance with good clinical practice and safety reporting obligations, and maintaining trial data integrity.
DNDi has established a Clinical Trials Task Force to evaluate the safety and feasibility of the conduct of our ongoing clinical trials, discuss the status of our studies and make recommendations to the senior executive regarding any necessary changes. The Clinical Trials Task Force is taking into consideration recently issued guidance from the World Health Organization, European Medicines Agency, and the U.S. Food and Drugs Administration, as well as national and local guidance.
The table below provides a summary of the status and any changes to planned and ongoing clinical trials. It will be updated as needed.
Last updated: 12 October 2021
We are working to coordinate clinical trials, facilitate and accelerate research, and advocate for accountability.
Get our latest news, personal stories, research articles, and job opportunities.